Open-label Brexpiprazole fMRI Trial in Adults With Major Depressive Disorder and Anxiety

• Status: Not yet recruiting
• Trial end date: 2023-04-05
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to use fMRI to evaluate the effects of brexpiprazole as add-on therapy to antidepressants on brain connectivity in individuals with MDD and symptoms of anxiety, aged 18 to 65.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
• Collaborator: H. Lundbeck A/S
• Treatments: Brexpiprazole

Criteria

Inclusion Criteria:

• 18 to 65 year of age

• Major Depressive Disorder (MDD) with symptoms of anxiety

• Stable treatment with less than 50% improvement

Exclusion Criteria:

• Contraindicated to perform fMRI scan

• Previous exposure to brexpiprazole